Buy & Sell CureVac BV (CVAC) – CureVac BV Price Today
Key Stats
- $1.05BMarket Cap
- HealthSector
- 0%3M Drawdown
- $599.28MEnterprise Value
- -Dividend Yield
- 21 daysTypical Hold Time
CureVac BV (CVAC) is currently valued at a market capitalization of $1.05B, with an enterprise value of $599.28M. Over the past 52 weeks, CureVac BV has traded between a low of $2.59 and a high of $5.6, highlighting its annual price range. Over the past three months, CureVac BV has recorded a drawdown of 0%, reflecting recent price volatility. CureVac BV offers a dividend yield of -. On average, investors hold CureVac BV for approximately 21 days, indicating typical investor behavior on the platform.
About CureVac BV
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
